Corcept Therapeutics Incorporated Stock Performance
| CORT Stock | USD 39.87 4.74 10.63% |
The firm shows a Beta (market volatility) of 2.66, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Corcept Therapeutics will likely underperform. At this point, Corcept Therapeutics has a negative expected return of -0.54%. Please make sure to confirm Corcept Therapeutics' total risk alpha, kurtosis, as well as the relationship between the Kurtosis and market facilitation index , to decide if Corcept Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Corcept Therapeutics Incorporated has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in March 2026. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return (10.63) | Five Day Return (13.81) | Year To Date Return 4.37 | Ten Year Return 1 K | All Time Return 226 |
1 | Disposition of 5287 shares by Guyer William of Corcept Therapeutics subject to Rule 16b-3 | 11/17/2025 |
2 | Disposition of 550000 shares by Belanoff Joseph K of Corcept Therapeutics at 3.88 subject to Rule 16b-3 | 12/24/2025 |
3 | A Look At Corcept Therapeutics Valuation After The FDA Complete Response Letter On Relacorilant | 01/12/2026 |
4 | Corcept Therapeutics Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50 percent Hagens Berman | 01/16/2026 |
5 | Insider Favorites 3 Growth Stocks With Strong Ownership | 01/21/2026 |
6 | INVESTOR ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT | 01/22/2026 |
7 | Corcept Therapeutics Climbs 13.7 percent on Strong Clinical Trial Results | 01/23/2026 |
8 | Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights - CORT | 01/29/2026 |
9 | Berman Tabacco Announces Investigation of Corcept Therapeutics Incorporated Concerning FDA New Drug Application | 01/30/2026 |
| Begin Period Cash Flow | 135.6 M | |
| Total Cashflows From Investing Activities | -177.6 M |
Corcept Therapeutics Relative Risk vs. Return Landscape
If you would invest 7,110 in Corcept Therapeutics Incorporated on November 4, 2025 and sell it today you would lose (3,123) from holding Corcept Therapeutics Incorporated or give up 43.92% of portfolio value over 90 days. Corcept Therapeutics Incorporated is currently does not generate positive expected returns and assumes 7.7062% risk (volatility on return distribution) over the 90 days horizon. In different words, 69% of stocks are less volatile than Corcept, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Corcept Therapeutics Target Price Odds to finish over Current Price
The tendency of Corcept Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 39.87 | 90 days | 39.87 | about 91.23 |
Based on a normal probability distribution, the odds of Corcept Therapeutics to move above the current price in 90 days from now is about 91.23 (This Corcept Therapeutics Incorporated probability density function shows the probability of Corcept Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 2.66 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Corcept Therapeutics will likely underperform. Additionally Corcept Therapeutics Incorporated has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Corcept Therapeutics Price Density |
| Price |
Predictive Modules for Corcept Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Corcept Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Corcept Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Corcept Therapeutics is not an exception. The market had few large corrections towards the Corcept Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Corcept Therapeutics Incorporated, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Corcept Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.63 | |
β | Beta against Dow Jones | 2.66 | |
σ | Overall volatility | 19.40 | |
Ir | Information ratio | -0.08 |
Corcept Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Corcept Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Corcept Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Corcept Therapeutics generated a negative expected return over the last 90 days | |
| Corcept Therapeutics has high historical volatility and very poor performance | |
| About 75.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from globenewswire.com: Berman Tabacco Announces Investigation of Corcept Therapeutics Incorporated Concerning FDA New Drug Application |
Corcept Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Corcept Stock often depends not only on the future outlook of the current and potential Corcept Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Corcept Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 113.5 M | |
| Cash And Short Term Investments | 383.3 M |
Corcept Therapeutics Fundamentals Growth
Corcept Stock prices reflect investors' perceptions of the future prospects and financial health of Corcept Therapeutics, and Corcept Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Corcept Stock performance.
| Return On Equity | 0.17 | ||||
| Return On Asset | 0.051 | ||||
| Profit Margin | 0.14 % | ||||
| Operating Margin | 0.05 % | ||||
| Current Valuation | 4.28 B | ||||
| Shares Outstanding | 105.19 M | ||||
| Price To Earning | 30.07 X | ||||
| Price To Book | 7.43 X | ||||
| Price To Sales | 5.67 X | ||||
| Revenue | 675.04 M | ||||
| Gross Profit | 727.78 M | ||||
| EBITDA | 138.29 M | ||||
| Net Income | 141.21 M | ||||
| Cash And Equivalents | 370.09 M | ||||
| Cash Per Share | 3.45 X | ||||
| Total Debt | 6.94 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 8.54 X | ||||
| Book Value Per Share | 6.01 X | ||||
| Cash Flow From Operations | 198.07 M | ||||
| Earnings Per Share | 0.78 X | ||||
| Market Capitalization | 4.2 B | ||||
| Total Asset | 840.55 M | ||||
| Retained Earnings | 543.74 M | ||||
| Working Capital | 330.83 M | ||||
| Current Asset | 48.98 M | ||||
| Current Liabilities | 20.88 M | ||||
About Corcept Therapeutics Performance
Assessing Corcept Therapeutics' fundamental ratios provides investors with valuable insights into Corcept Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Corcept Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 478.77 | 454.83 | |
| Return On Tangible Assets | 0.15 | 0.16 | |
| Return On Capital Employed | 0.20 | 0.18 | |
| Return On Assets | 0.15 | 0.16 | |
| Return On Equity | 0.21 | 0.19 |
Things to note about Corcept Therapeutics performance evaluation
Checking the ongoing alerts about Corcept Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Corcept Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Corcept Therapeutics generated a negative expected return over the last 90 days | |
| Corcept Therapeutics has high historical volatility and very poor performance | |
| About 75.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from globenewswire.com: Berman Tabacco Announces Investigation of Corcept Therapeutics Incorporated Concerning FDA New Drug Application |
- Analyzing Corcept Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Corcept Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Corcept Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Corcept Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Corcept Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Corcept Therapeutics' stock. These opinions can provide insight into Corcept Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Corcept Stock Analysis
When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.